BIOMAT Database Logo BIOMAT Database Logo

Debrisoquine hydroxylation polymorphism and personality. 1989

L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D010551 Personality Behavior-response patterns that characterize the individual. Personalities
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D005260 Female Females
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations

Related Publications

L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
Debrisoquine hydroxylation polymorphism in diabetic patients.
November 1990, Diabetes research (Edinburgh, Scotland),
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
June 1994, Pharmacogenetics,
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
February 1993, Pharmacology & toxicology,
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
November 1988, British journal of clinical pharmacology,
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.
September 1984, Lancet (London, England),
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
December 1984, Lancet (London, England),
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
Relationship between Type A and B personality and debrisoquine hydroxylation capacity.
June 2004, British journal of clinical pharmacology,
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
December 2013, Pharmacogenomics,
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
A study of the debrisoquine hydroxylation polymorphism in a Nigerian population.
November 1980, Xenobiotica; the fate of foreign compounds in biological systems,
L Bertilsson, and C Alm, and C De Las Carreras, and J Widen, and G Edman, and D Schalling
Polymorphic hydroxylation of debrisoquine.
October 1977, Lancet (London, England),
Copied contents to your clipboard!